A Ribonucleoprotein Approach to Boost the STING Signaling for Cancer Immunotherapy
Invention type: Technology
/
Case number: #21216
Researchers
Departments: David H Koch Institute for Integrative Cancer Res, Office of the Provost
Technology Areas: Therapeutics: Nucleic Acids, Proteins & Antibodies
Impact Areas: Healthy Living
-
ribonucleoprotein approach to boost the sting signaling for cancer immunotherapy
United States of America | Published application
License this technology
Interested in this technology? Connect with our experienced licensing team to initiate the process.
Sign up for technology updates
Sign up now to receive the latest updates on cutting-edge technologies and innovations.